132 related articles for article (PubMed ID: 35993503)
1. Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease.
Liu TT; Qiu H; Liu SY; Chien C; Wang JH; Wong MW; Yi CH; Lin L; Lei WY; Liang SW; Hung JS; Huang JF; Chen CL; Han MAT
Kaohsiung J Med Sci; 2022 Oct; 38(10):1012-1019. PubMed ID: 35993503
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
[TBL] [Abstract][Full Text] [Related]
3. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.
Padole P; Arora A; Sharma P; Chand P; Verma N; Kumar A
J Clin Exp Hepatol; 2022; 12(2):435-439. PubMed ID: 35535066
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
5. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
[TBL] [Abstract][Full Text] [Related]
6. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
Avcu A; Kaya E; Yilmaz Y
Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
[TBL] [Abstract][Full Text] [Related]
8. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
Demir M; Deyneli O; Yılmaz Y
Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.
Lukenda Zanko V; Domislovic V; Trkulja V; Krznaric-Zrnic I; Turk-Wensveen T; Krznaric Z; Filipec Kanizaj T; Radic-Kristo D; Bilic-Zulle L; Orlic L; Dinjar-Kujundzic P; Poropat G; Stimac D; Hauser G; Mikolasevic I
Diabetes Obes Metab; 2020 Nov; 22(11):2097-2106. PubMed ID: 32613718
[TBL] [Abstract][Full Text] [Related]
10. When the liver gets stiff, the tough get moving.
Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
[TBL] [Abstract][Full Text] [Related]
11. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
Lefere S; Dupont E; De Guchtenaere A; Van Biervliet S; Vande Velde S; Verhelst X; Devisscher L; Van Vlierberghe H; Geerts A; De Bruyne R
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2317-2326.e4. PubMed ID: 34871812
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
14. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
16. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status.
Huh JH; Kim KJ; Kim SU; Han SH; Han KH; Cha BS; Chung CH; Lee BW
Metabolism; 2017 Jan; 66():23-31. PubMed ID: 27923446
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
[TBL] [Abstract][Full Text] [Related]
18. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
[TBL] [Abstract][Full Text] [Related]
19. A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients.
Nachit M; Lanthier N; Rodriguez J; Neyrinck AM; Cani PD; Bindels LB; Hiel S; Pachikian BD; Trefois P; Thissen JP; Delzenne NM
JHEP Rep; 2021 Aug; 3(4):100323. PubMed ID: 34355155
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
